Comparison of Prognostic Outcomes Between Repeat Liver Resection and Particle Therapy for Patients with Recurrent Hepatocellular Carcinoma.
Multidisciplinary treatment
Particle therapy
Propensity score matching
Recurrent hepatocellular carcinoma
Repeat liver resection
Treatment-related complications
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
25
06
2024
accepted:
30
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
Particle therapy (PT) as an initial hepatocellular carcinoma (HCC) treatment has been reported to be effective; however, its efficacy for the treatment of recurrent HCC remains unclear. This study aimed to evaluate the efficacy of PT compared with repeat liver resection for treating recurrent HCC after initial LR, with a focus on prognostic outcomes. Between 2005 and 2019, 89 and 49 patients underwent repeat LR and PT for recurrent HCC after initial LR, respectively. The 5-year overall survival (OS) and recurrence-free survival (RFS) were evaluated using propensity score matching. Treatment-related complications were scored using the National Institute Common Terminology Criteria for Adverse Events (CTCAE) and were compared between the repeat LR and PT groups. In the entire cohort, the 5-year OS was significantly better in the repeat LR group than in the PT group (75% vs. 48%; p = 0.0003), and the 5-year RFS was comparable in both groups (22% vs. 13%; p = 0.088). Propensity score matching created 34 pairs of patients; no significant differences in the 5-year OS (65% vs. 48%; p = 0.310) and RFS (21% vs. 8%; p = 0.271) were observed between the repeat LR and PT groups. The proportion of CTCAE grade ≥3 complications was 8.8% and 5.9% in the repeat LR and PT groups, respectively (p = 0.641). After initial LR, the prognosis and treatment-related complications in patients with recurrent HCC were comparable between the repeat LR and PT groups in the matched cohort; therefore, PT may remain one of the multidisciplinary treatment options for recurrent HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Particle therapy (PT) as an initial hepatocellular carcinoma (HCC) treatment has been reported to be effective; however, its efficacy for the treatment of recurrent HCC remains unclear.
OBJECTIVE
OBJECTIVE
This study aimed to evaluate the efficacy of PT compared with repeat liver resection for treating recurrent HCC after initial LR, with a focus on prognostic outcomes.
METHODS
METHODS
Between 2005 and 2019, 89 and 49 patients underwent repeat LR and PT for recurrent HCC after initial LR, respectively. The 5-year overall survival (OS) and recurrence-free survival (RFS) were evaluated using propensity score matching. Treatment-related complications were scored using the National Institute Common Terminology Criteria for Adverse Events (CTCAE) and were compared between the repeat LR and PT groups.
RESULTS
RESULTS
In the entire cohort, the 5-year OS was significantly better in the repeat LR group than in the PT group (75% vs. 48%; p = 0.0003), and the 5-year RFS was comparable in both groups (22% vs. 13%; p = 0.088). Propensity score matching created 34 pairs of patients; no significant differences in the 5-year OS (65% vs. 48%; p = 0.310) and RFS (21% vs. 8%; p = 0.271) were observed between the repeat LR and PT groups. The proportion of CTCAE grade ≥3 complications was 8.8% and 5.9% in the repeat LR and PT groups, respectively (p = 0.641).
CONCLUSIONS
CONCLUSIONS
After initial LR, the prognosis and treatment-related complications in patients with recurrent HCC were comparable between the repeat LR and PT groups in the matched cohort; therefore, PT may remain one of the multidisciplinary treatment options for recurrent HCC.
Identifiants
pubmed: 39453585
doi: 10.1245/s10434-024-16363-w
pii: 10.1245/s10434-024-16363-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer. 2014;120:2824–38. https://doi.org/10.1002/cncr.28730 .
doi: 10.1002/cncr.28730
pubmed: 24897995
Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35. https://doi.org/10.1097/01.sla.0000197706.21803.a1 .
doi: 10.1097/01.sla.0000197706.21803.a1
pubmed: 16432356
pmcid: 1448919
Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med. 2008;359:2045–7. https://doi.org/10.1056/nejme0807581 .
doi: 10.1056/nejme0807581
pubmed: 18923166
Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71–8. https://doi.org/10.1097/00000658-200107000-00011 .
doi: 10.1097/00000658-200107000-00011
pubmed: 11420485
pmcid: 1421950
Lee KF, Chong CCN, Fong AKW, et al. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr. 2018;7:320–30. https://doi.org/10.21037/hbsn.2018.03.17 .
doi: 10.21037/hbsn.2018.03.17
pubmed: 30498708
pmcid: 6230848
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93. https://doi.org/10.1016/j.jhep.2021.11.018 .
doi: 10.1016/j.jhep.2021.11.018
pubmed: 34801630
Yang YQ, Wen ZY, Liu XY, et al. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol. 2023;15:129–50. https://doi.org/10.4254/wjh.v15.i2.129 .
doi: 10.4254/wjh.v15.i2.129
pubmed: 36926237
pmcid: 10011906
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–55. https://doi.org/10.1097/sla.0000000000000710 .
doi: 10.1097/sla.0000000000000710
pubmed: 25010665
Nakajima Y, Ko S, Kanamura T, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg. 2001;192:339–44. https://doi.org/10.1016/s1072-7515(00)00789-4 .
doi: 10.1016/s1072-7515(00)00789-4
pubmed: 11245376
Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10. https://doi.org/10.1097/01.sla.0000094549.11754.e6 .
doi: 10.1097/01.sla.0000094549.11754.e6
pubmed: 14578733
pmcid: 1356149
Oh JH, Sinn DH, Choi GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res. 2020;99:238–46. https://doi.org/10.4174/astr.2020.99.4.238 .
doi: 10.4174/astr.2020.99.4.238
pubmed: 33029483
pmcid: 7520230
Liu J, Zhao J, Gu HAO, Zhu Z. Repeat hepatic resection vs radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis. Minim Invasive Ther Allied Technol. 2022;31:332–41. https://doi.org/10.1080/13645706.2020.1839775 .
doi: 10.1080/13645706.2020.1839775
pubmed: 33143517
Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21:758–66. https://doi.org/10.1245/s10434-013-3254-5 .
doi: 10.1245/s10434-013-3254-5
pubmed: 24006095
Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol. 2015;41:236–42. https://doi.org/10.1016/j.ejso.2014.11.002 .
doi: 10.1016/j.ejso.2014.11.002
pubmed: 25434327
de Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol. 2015;21:11185–98. https://doi.org/10.3748/wjg.v21.i39.11185 .
doi: 10.3748/wjg.v21.i39.11185
Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: an intent-to-treat analysis. Liver Transpl. 2017;23:1553–63. https://doi.org/10.1002/lt.24952 .
doi: 10.1002/lt.24952
pubmed: 28945955
Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890–904. https://doi.org/10.1002/cncr.26134 .
doi: 10.1002/cncr.26134
pubmed: 21495022
Kasuya G, Kato H, Yasuda S, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer. 2017;123:3955–65. https://doi.org/10.1002/cncr.30816 .
doi: 10.1002/cncr.30816
pubmed: 28662297
Komatsu S, Murakami M, Fukumoto T, et al. Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinoma. Br J Surg. 2011;98:558–64. https://doi.org/10.1002/bjs.7397 .
doi: 10.1002/bjs.7397
pubmed: 21246516
Omiya S, Komatsu S, Terashima K, et al. Hepatic resection vs particle therapy as an initial treatment for single hepatocellular carcinoma: bi-institutional propensity score-matched analysis. J Am Coll Surg. 2023;236:972–81. https://doi.org/10.1097/xcs.0000000000000532 .
doi: 10.1097/xcs.0000000000000532
pubmed: 36537706
Mizumoto M, Ogino H, Okumura T, et al. Proton beam therapy for hepatocellular carcinoma: multicenter prospective registry study in Japan. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.09.047 .
doi: 10.1016/j.ijrobp.2023.09.047
pubmed: 37778422
Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325–36. https://doi.org/10.1159/000479984 .
doi: 10.1159/000479984
pubmed: 29234636
pmcid: 5704689
Hiraoka A, Kumada T, Tsuji K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2019;8:121–9. https://doi.org/10.1159/000488778 .
doi: 10.1159/000488778
pubmed: 31019902
Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304. https://doi.org/10.1002/ssu.2980090404 .
doi: 10.1002/ssu.2980090404
pubmed: 8210909
Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11:3799–805. https://doi.org/10.1158/1078-0432.ccr-04-1350 .
doi: 10.1158/1078-0432.ccr-04-1350
pubmed: 15897579
Yoh T, Seo S, Taura K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival. Ann Surg. 2021;273:792–9. https://doi.org/10.1097/sla.0000000000003358 .
doi: 10.1097/sla.0000000000003358
pubmed: 31058698
Bednarsch J, Czigany Z, Heij LR, et al. The role of re-resection in recurrent hepatocellular carcinoma. Langenbecks Arch Surg. 2022;407:2381–91. https://doi.org/10.1007/s00423-022-02545-1 .
doi: 10.1007/s00423-022-02545-1
pubmed: 35599252
pmcid: 9468093
Mise Y, Hasegawa K, Shindoh J, et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 2015;262:347–57. https://doi.org/10.1097/sla.0000000000000882 .
doi: 10.1097/sla.0000000000000882
pubmed: 25185473
Stockmann M, Lock JF, Riecke B, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–25. https://doi.org/10.1097/sla.0b013e3181ad85b5 .
doi: 10.1097/sla.0b013e3181ad85b5
pubmed: 19561474
Ferrante ND, Pillai A, Singal AG. Update on the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2020;16:506–16.
Byun HK, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2023;29:945–57. https://doi.org/10.3350/cmh.2023.0217 .
doi: 10.3350/cmh.2023.0217
pubmed: 37583055
pmcid: 10577350
Mizumoto M, Okumura T, Hashimoto T, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:e529–35. https://doi.org/10.1016/j.ijrobp.2011.05.056 .
doi: 10.1016/j.ijrobp.2011.05.056
pubmed: 22284041
Vitale A, Farinati F, Noaro G, et al. Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study. Hepatology. 2018;68:1232–44. https://doi.org/10.1002/hep.30185 .
doi: 10.1002/hep.30185
pubmed: 30048016
Huo TI, Lui WY, Wu JC, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg. 2004;28:258–62. https://doi.org/10.1007/s00268-003-7182-6 .
doi: 10.1007/s00268-003-7182-6
pubmed: 14961198
Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–6. https://doi.org/10.1016/j.ijrobp.2008.10.073 .
doi: 10.1016/j.ijrobp.2008.10.073
pubmed: 19304408
Kishi Y, Nara S, Esaki M, Hiraoka N, Shimada K. Salvage hepatectomy for local recurrence of hepatocellular carcinomas offers survival comparable to that of matched patients who undergo primary hepatectomies. Eur J Surg Oncol. 2017;43:1076–82. https://doi.org/10.1016/j.ejso.2017.03.021 .
doi: 10.1016/j.ejso.2017.03.021
pubmed: 28456443
Tanaka M, Komatsu S, Kido M, et al. Salvage hepatectomy for local recurrence after particle therapy using proton and carbon ion beams for liver cancer. Ann Gastroenterol Surg. 2021;5:711–9. https://doi.org/10.1002/ags3.12468 .
doi: 10.1002/ags3.12468
pubmed: 34585055
pmcid: 8452475
Kobeissi JM, Hilal L, Simone CB, et al. Proton therapy in the management of hepatocellular carcinoma. Cancers. 2022;14:2900. https://doi.org/10.3390/cancers14122900 .
doi: 10.3390/cancers14122900
pubmed: 35740567
pmcid: 9220794
Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114:289–95. https://doi.org/10.1016/j.radonc.2014.11.033 .
doi: 10.1016/j.radonc.2014.11.033
pubmed: 25497556
Lee SU, Kim TH. Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma. Clin Mol Hepatol. 2023;29:958–68. https://doi.org/10.3350/cmh.2023.0274 .
doi: 10.3350/cmh.2023.0274
pubmed: 37822213
pmcid: 10577334